Abstract
Purpose of Review
CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) is an important disease to consider in the differential diagnosis of migraine with aura. This review examines current literature regarding migraine in CADASIL, as well as diagnostic and treatment modalities.
Recent Findings
Recent studies have shown that smoking is a modifiable risk factor for progression of CADASIL (Chabriat et al. in Stroke 47:4–11, 2015). Specific imaging changes and findings on clinical exam can predict disease progression. However, migraine symptoms often precede MRI changes (Guey et al. in Cephalalgia 36:1038–47, 2015). A recent paper on migraine treatment in CADASIL reevaluates the prevailing belief that vasoconstrictive abortive medications are contraindicated in these patients (Tan and Markus in PLoS ONE 11:e0157613, 2016).
Summary
CADASIL is an autosomal dominantly inherited vasculopathy causing ischemic pathology in younger individuals due to a mutation in the NOTCH3 gene. The mutation results in impaired arterial contractility due to accumulation of granular osmiophilic extracellular material (GOM) in vascular smooth muscle cells (VSMCs). Clinical manifestations include migraine with and without aura, cognitive decline, ischemic events, and mood disorders. The presenting symptom is often migraine with aura. Characteristic MRI changes are often present. Genetic screening is available to confirm NOTCH3 mutation and pathognomic changes are often seen in skin biopsy. Treatment of migraine is similar to the general population, but with some notable and specific differences. Further studies in CADASIL, other small vessel arteriopathies, and migraine may help us understand more about the pathophysiology of these conditions and help with treatment development.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
• Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser M. CADASIL. Lancet Neurol. 2009;8:643–53. Comprehensive review article from 2009 discussing pathophysiology, symptoms, diagnosis, treatment and progression.
Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996;383:707–10.
• Tikka S, Baumann M, Siitonen M, et al. CADASIL and CARASIL. Brain Pathol. 2014;24:525–44. Recent article on the genetics and pathology of CADASIL and CARASIL.
Kalimo H, Ruchoux M, Viitanen M, Kalaria R. CADASIL: a common form of hereditary arteriopathy causing brain infarcts and dementia. Brain Pathol. 2002;12:371–84.
Joutel A, Andreux F, Gaulis S, Domenga V, Cecillon M, Battail N, et al. The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Investig. 2000;105:597–605.
Chabriat H, Vahedi K, Bousser M, et al. Clinical spectrum of CADASIL: a study of 7 families. Lancet. 1995;346:934–9.
Ruchoux M, Maurage C. CADASIL. J Neuropathol Exp Neurol. 1997;56:947–64.
Dichgans M, Mayer M, Uttner I, Brüning R, Müller-Höcker J, Rungger G, et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol. 1998;44:731–9.
Liem M, Oberstein S, van der Grond J, Ferrari M, Haan J. CADASIL and migraine: a narrative review. Cephalalgia. 2010;30:1284–9.
• Guey S, Mawet J, Herve D, Duering M, Godin O, Jouvent E, et al. Prevalence and characteristics of migraine in CADASIL. Cephalalgia. 2015;36:1038–47. Prospective cohort of 378 CADASIL patients evaluating migraine symptoms and possible correlates with symptoms, severity and MRI findings.
Gunda B, Herve D, Godin O, et al. Effects of gender on the phenotype of CADASIL. Stroke. 2011;43:137–41.
•• Tan R, Markus H. CADASIL: migraine, encephalopathy, stroke and their inter-relationships. PLoS ONE. 2016;11:e0157613. Recently completed prospective study with 300 symptomatic CADASIL patients examining migraine patterns, treatment responses and associations between migraine, stroke and encephalopathy. First article to document use of vasoconstrictive treatment with triptans and ergots in CADASIL patients.
Adib-Samii P, Brice G, Martin R, Markus H. Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype: study in 200 consecutively recruited individuals. Stroke. 2010;41:630–4.
Vahedi K, Chabriat H, Levy C, Joutel A, Tournier-Lasserve E, Bousser M. Migraine with aura and brain magnetic resonance imaging abnormalities in patients with CADASIL. Arch Neurol. 2004. doi:10.1001/archneur.61.8.1237.
• Zhu S, Nahas S. CADASIL: imaging characteristics and clinical correlation. Curr Pain Headache Rep. 2016. doi:10.1007/s11916-016-0584-6. Recent article reviewing imaging findings in CADASIL and correlation with clinical symptoms.
Desmond D, Moroney J, Lynch T, Chan S, Chin S, Mohr J. The natural history of CADASIL : a pooled analysis of previously published cases. Stroke. 1999;30:1230–3.
Liem M, Lesnik Oberstein S, Haan J, van der Neut I, van den Boom R, Ferrari M, et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: progression of MR abnormalities in prospective 7-year Follow-up Study. Radiology. 2008;249:964–71.
Chabriat H, Mrissa R, Levy C, Vahedi K, Taillia H, Iba-Zizen M, et al. Brain stem MRI signal abnormalities in CADASIL. Stroke. 1999;30:457–9.
Viswanathan A. Blood pressure and haemoglobin A1c are associated with microhaemorrhage in CADASIL: a two-centre cohort study. Brain. 2006;129:2375–83.
Peters N, Holtmannspotter M, Opherk C, Gschwendtner A, Herzog J, Samann P, et al. Brain volume changes in CADASIL: a serial MRI study in pure subcortical ischemic vascular disease. Neurology. 2006;66:1517–22.
Peters N, Opherk C, Bergmann T, Castro M, Herzog J, Dichgans M. Spectrum of mutations in biopsy-proven CADASIL. Arch Neurol. 2005;62:1091.
•• Chabriat H, Hervé D, Duering M, et al. Predictors of clinical worsening in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke. 2015;47:4–11. Prospective cohort study of 290 CADASIL patients evaluating for demographic, clinical, and MRI predictors of stroke, dementia, clinical worsening and death. Underlines importance of imaging and exam in predicting disease progression and showed that smoking is a modifiable risk factor for progression.
Forteza A, Brozman B, Rabinstein A, Romano J, Bradley W. Acetazolamide for the treatment of migraine with aura in CADASIL. Neurology. 2001;57:2144–5.
• Donnini I, Nannucci S, Valenti R, Pescini F, Bianchi S, Inzitari D, et al. Acetazolamide for the prophylaxis of migraine in CADASIL: a preliminary experience. J Headache Pain. 2012;13:299–302. Retrospective study looking at 7 patients treated with acetazolamide for migraine prophylaxis and their responses.
• Ferrari M, Klever R, Terwindt G, Ayata C, van den Maagdenberg A. Migraine pathophysiology: lessons from mouse models and human genetics. Lancet Neurol. 2015;14:65–80. Review article summarizing recent findings in mouse models and possible connections in humans in regards to migraine and aura pathophysiology.
Brennan K, Beltran-Parrazal L, Lopez-Valdes H, Theriot J, Toga A, Charles A. Distinct vascular conduction with cortical spreading depression. J Neurophysiol. 2007;97:4143–51.
Hadjikhani N, Sanchez del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci. 2001;98:4687–92.
Haffner C, Vinters H. CADASIL, CARASIL, CARASAL. Neurology. 2016;87:1752–3.
Chabriat H, Tournier-Lasserve E, Vahedi K, et al. Autosomal dominant migraine with MRI white-matter abnormalities mapping to the CADASIL locus. Neurology. 1995;45:1086–91.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Dr. John Glenn Burkett and Dr. Carrie Dougherty each declare no potential conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Uncommon and/or Unusual Headaches and Syndromes
Rights and permissions
About this article
Cite this article
Burkett, J.G., Dougherty, C. Recognizing CADASIL: a Secondary Cause of Migraine with Aura. Curr Pain Headache Rep 21, 21 (2017). https://doi.org/10.1007/s11916-017-0621-0
Published:
DOI: https://doi.org/10.1007/s11916-017-0621-0